Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients

Edvan De Queiroz Crusoe,Joanna Leal,Marco Aurelio Salvino,Larissa Ferreira Lucas,Juliana Andrade Santos,Herbert Henrique de Melo Santos,Alessandro de M. Almeida,Allan de souza Santos,Marcos Chaves,Mariane Melo Santos,Sarah Queiroz Silva,Lucas de Oliveira Vieira,Cleverson Alves Fonseca,Elisangela Adorno,Vania Hungria,Maria da Gloria B. Arruda

Blood（2021）

引用 0|浏览9

暂无评分

摘要

Background: Newly drugs access for MM treatment still a challenge in some countries. One of the most available inductions for TE NDMM patients (pts) worldwide is cyclophosphamide (C), thalidomide (T) and dexamethasone (d)-(CTd). Dara the first anti- CD38, had been combined with VCd, VTd and VRd and markedly increased the depth and duration of the response. We hypothesized that Dara and CTd combination could be safe and allow deeper activity as an alternative protocol.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要